Literature DB >> 19695877

Genetic variants in the promoter of TARDBP in sporadic amyotrophic lateral sclerosis.

Natasha Luquin1, Bing Yu, Rebecca B Saunderson, Ronald J Trent, Roger Pamphlett.   

Abstract

All patients with sporadic amyotrophic lateral sclerosis (SALS) have TDP-43 inclusions in their motor neurons, suggesting this protein plays a major role in the disease. Coding mutations in the gene for TDP-43, TARDBP, have been found in only a few patients with SALS. However, the non-coding regulatory regions of TARDBP have not yet been examined in SALS. We therefore sequenced both coding and non-coding regions of TARDBP in 46 tissue-banked SALS brains (brain DNA was used to detect somatic mutations). Non-coding variants (in the promoter or intron 1) were detected in 16 patients (35%) and coding variants in 4 (9%). Two known promoter variants were found more frequently in SALS patients than in controls. Two other variants, found in one patient each but not in controls, have potential regulatory functions. In addition, a novel exon 2 change with predicted functional effects was found in one patient. In summary, variants in the promoter and other non-coding regions of TARDBP may disturb the regulation of this gene in some patients with SALS.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19695877     DOI: 10.1016/j.nmd.2009.07.005

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  10 in total

Review 1.  TDP-43 and FUS/TLS: emerging roles in RNA processing and neurodegeneration.

Authors:  Clotilde Lagier-Tourenne; Magdalini Polymenidou; Don W Cleveland
Journal:  Hum Mol Genet       Date:  2010-04-15       Impact factor: 6.150

Review 2.  The complex molecular biology of amyotrophic lateral sclerosis (ALS).

Authors:  Rachel L Redler; Nikolay V Dokholyan
Journal:  Prog Mol Biol Transl Sci       Date:  2012       Impact factor: 3.622

Review 3.  TARDBP mutation analysis in TDP-43 proteinopathies and deciphering the toxicity of mutant TDP-43.

Authors:  Tania F Gendron; Rosa Rademakers; Leonard Petrucelli
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

Review 4.  FTD and ALS: a tale of two diseases.

Authors:  R Ferrari; D Kapogiannis; E D Huey; P Momeni
Journal:  Curr Alzheimer Res       Date:  2011-05       Impact factor: 3.498

5.  Progranulin is neurotrophic in vivo and protects against a mutant TDP-43 induced axonopathy.

Authors:  Angela S Laird; Annelies Van Hoecke; Louis De Muynck; Mieke Timmers; Ludo Van den Bosch; Philip Van Damme; Wim Robberecht
Journal:  PLoS One       Date:  2010-10-13       Impact factor: 3.240

6.  Characterization of the human TARDBP gene promoter.

Authors:  Marco Baralle; Maurizio Romano
Journal:  Sci Rep       Date:  2021-05-17       Impact factor: 4.379

7.  Altered RNA metabolism and amyotrophic lateral sclerosis.

Authors:  Ashok Verma
Journal:  Ann Indian Acad Neurol       Date:  2011-10       Impact factor: 1.383

Review 8.  Interpretation of mRNA splicing mutations in genetic disease: review of the literature and guidelines for information-theoretical analysis.

Authors:  Natasha Caminsky; Eliseos J Mucaki; Peter K Rogan
Journal:  F1000Res       Date:  2014-11-18

Review 9.  A network of RNA and protein interactions in Fronto Temporal Dementia.

Authors:  Francesca Fontana; Kavitha Siva; Michela A Denti
Journal:  Front Mol Neurosci       Date:  2015-03-19       Impact factor: 5.639

10.  Can ALS-associated C9orf72 repeat expansions be diagnosed on a blood DNA test alone?

Authors:  Roger Pamphlett; Pak Leng Cheong; Ronald J Trent; Bing Yu
Journal:  PLoS One       Date:  2013-07-19       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.